Mandate

Vinge advises Sigrid Therapeuctis AB on share issues

November 27, 2017

Vinge has advised Sigrid Therapeuctis AB in connection with a combined directed issue and rights offering.

Sigrid Therapeutics is pioneering a user-friendly product made of precisely engineered particles with extraordinary absorptive capacity. The product works mechanically in the gut to improve glycemic control in a safe and effective way.

Vinge’s team primarily consisted of Kristoffer Franzkeit and Astrid Karlsson.

Related

Vinge advises Lagercrantz Group in conjunction with the acquisition of Stalon

Lagercrantz Group Aktiebolag has acquired 88 per cent of the shares in Stalon AB, a Swedish manufacturer of silencers for hunting firearms. The company is based in Stalon, which is located outside Vilhelmina, where the company conducts development and production in its own facilities.
May 21, 2026

Vinge advises PPI Public Property Invest AB (publ) in connection with cross-border merger and listing on Nasdaq Stockholm and Euronext Oslo Børs

Vinge has advised PPI Public Property Invest AB (publ) (“PPI”) in connection with its listing on Nasdaq Stockholm and secondary listing on Euronext Oslo Børs. The listing was carried out through a cross-border merger whereby PPI absorbed Public Property Invest ASA, whose shares were previously listed on Euronext Oslo Børs.
May 20, 2026

Vinge represents Triton in connection with the sale of Aleris

Vinge has represented Triton in connection with the sale of Aleris to Mehiläinen Group.
May 18, 2026